ACIP更新:Janssen与mRNA新冠疫苗接种后不良事件报告下的疫苗使用建议
2021年7月ACIP基于Janssen疫苗后血栓伴血小板减少综合征和格林-巴利综合征报告,以及mRNA疫苗后心肌炎报告,评估成人接种获益与风险。ACIP判定≥18岁成人接种获益总体超过罕见严重不良事件风险,但获益风险平衡随年龄和性别而异,继续推荐≥12岁人群接种。
要点
- ACIP评估Janssen疫苗后TTS和GBS、mRNA疫苗后心肌炎报告,判定成人接种总体获益大于风险。
- 获益与风险平衡随年龄和性别不同,应据此向接种者和公众传递风险信息。
- ACIP继续推荐所有≥12岁人群接种新冠疫苗。
核心结论
- ACIP判定在≥18岁成人中,新冠疫苗接种预防发病和死亡的总体获益超过这些罕见严重不良事件的风险。
- 该获益与风险的平衡随年龄和性别而异。
- ACIP继续推荐所有≥12岁人群接种新冠疫苗。
研究设计与样本
- ACIP于2021年7月召开会议,审查Janssen疫苗后TTS和GBS报告及mRNA疫苗后心肌炎报告的数据。
- ACIP综合评估了接种这些疫苗的获益与风险。
主要发现
- Janssen新冠疫苗接种后报告了血栓伴血小板减少综合征(TTS)和格林-巴利综合征(GBS)。
- Pfizer-BioNTech或Moderna新冠疫苗接种后报告了心肌炎,尤其在第二剂后;二者合称mRNA新冠疫苗接种。
关键数值与推荐
- Pfizer-BioNTech疫苗获授权并推荐用于≥12岁人群。
- Moderna和Janssen疫苗获授权并推荐用于≥18岁人群。
- Pfizer-BioNTech和Moderna疫苗为2剂系列mRNA疫苗;Janssen疫苗为单剂重组复制缺陷型腺病毒载体疫苗。
临床怎么用
- 向提供者、疫苗受种者和公众传播有关风险及其随年龄、性别和疫苗类型变化的信息。
- CDC和FDA继续密切监测严重不良事件报告,并将向ACIP提交额外数据供审议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for Pfizer-BioNTech and Moderna COVID-19 vaccines, and in February 2021, FDA issued an EUA for the Janssen (Johnson & Johnson) COVID-19 vaccine. After each EUA, the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for vaccine use; currently Pfizer-BioNTech is authorized and recommended for persons aged ≥12 years and Moderna and Janssen for persons aged ≥18 years (1-3). Both Pfizer-BioNTech and Moderna vaccines, administered as 2-dose series, are mRNA-based COVID-19 vaccines, whereas the Janssen COVID-19 vaccine, administered as a single dose, is a recombinant replication-incompetent adenovirus-vector vaccine. As of July 22, 2021, 187 million persons in the United States had received at least 1 dose of COVID-19 vaccine (4); close monitoring of safety surveillance has demonstrated that serious adverse events after COVID-19 vaccination are rare (5,6). Three medical conditions have been reported in temporal association with receipt of COVID-19 vaccines. Two of these (thrombosis with thrombocytopenia syndrome [TTS], a rare syndrome characterized by venous or arterial thrombosis and thrombocytopenia, and Guillain-Barré syndrome [GBS], a rare autoimmune neurologic disorder characterized by ascending weakness and paralysis) have been reported after Janssen COVID-19 vaccination. One (myocarditis, cardiac inflammation) has been reported after Pfizer-BioNTech COVID-19 vaccination or Moderna COVID-19 vaccination, particularly after the second dose; these were reviewed together and will hereafter be referred to as mRNA COVID-19 vaccination. ACIP has met three times to review the data associated with these reports of serious adverse events and has comprehensively assessed the benefits and risks associated with receipt of these vaccines. During the most recent meeting in July 2021, ACIP determined that, overall, the benefits of COVID-19 vaccination in preventing COVID-19 morbidity and mortality outweigh the risks for these rare serious adverse events in adults aged ≥18 years; this balance of benefits and risks varied by age and sex. ACIP continues to recommend COVID-19 vaccination in all persons aged ≥12 years. CDC and FDA continue to closely monitor reports of serious adverse events and will present any additional data to ACIP for consideration. Information regarding risks and how they vary by age and sex and type of vaccine should be disseminated to providers, vaccine recipients, and the public.
引用
- Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34383735. doi:10.15585/mmwr.mm7032e4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。